IDH1 and oligodendroglial tumor: Interestingly, there is a subset of anaplastic oligodendroglial tumors characterized by 1p19q loss of heterozygosity (LOH) and IDH1 mutations that significantly benefits from procarbazine, CCNU, and vincristine (PCV) chemotherapy [35].